Given that high expression of ALDH1 and CD133 in ovarian tumors is strongly associated with poor prognosis and chemoresistance [78,79,80,81,82], we conclude that prolonged treatment of cisplatin-resistant HGSOC with trametinib might promote CSC enrichment. Here, PROM1 is linked to ovarian neoplasm.